Summit Therapeutics Inc.
NASDAQSMMT enters the final week of September carrying a striking disconnect: the stock is up 30% in a month, yet short sellers have added to their positions by nearly 18% over the same period. The analyst story is the most important development of recent weeks. Jefferies made the boldest call, upgrading from Hold to Buy on September 9 and lifting its target from $15 to $25 — a signal…
SMMT upgrades to Buy from Hold; Jefferies raises PT 67% to $25 vs. $17.28 close.
SMMT enters the final week of September carrying a striking disconnect: the stock is up 30% in a month, yet short sellers have added to their positions by nearly 18% over the same period. The analyst story is the most…
SMMT heads into the final days of August with a clear divergence between two analyst camps — and a $50 million insider vote of confidence from the top of the company still sitting in recent memory. The most notable…
Snapshot as of 25 Sept 2026
SMMT enters the second half of August with an unusual alignment — shorts are covering, options traders are increasingly bullish, and insiders are buying with conviction, all while the Street remains deeply divided on…
Summit Therapeutics reports Q2 results tonight — and the setup is defined less by short positioning than by an unusually loud insider conviction signal meeting an equally divided analyst community. The insider story…
Summit Therapeutics enters its Q2 earnings release — scheduled for July 23 after hours — with a striking insider conviction signal, a rebuilding short position, and an analyst community that remains deeply divided. The…
Summit Therapeutics enters July with a striking insider conviction signal: the company's own executives and chairman put more than $52 million of their own money into the stock in early June, even as the share price…
Summit Therapeutics exited its June 10 earnings print with an unusual split: insiders loading up on stock while short sellers simultaneously rebuilt positions at the fastest weekly pace in months, setting up a…
Summit Therapeutics heads into its June 10 earnings report with its own executives making a conspicuous case for the stock just days before the release. On June 4, CEO Maky Zanganeh purchased 100,000 shares at $14.60 —…
Summit Therapeutics heads into its May 4 Q1 print riding a sharp reversal — up 26% in a month — while options traders quietly lean more bullish than at almost any point this year. The clearest positioning signal is in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SMMT — free to start on ORTEX.
Sign up for free →Open SMMT on ORTEX